Darolutamide

Definition

A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.

Also known as Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, DAROLUTAMIDE, Nubeqa, ODM 201, ODM-201, ODM201 — per NCIT

Also identified as

• ATC L02BB06 per RXNORM
• NCIT NCIT:C104748 per NCIT
• SCTID 789148001 per RXNORM
• SCTID 789166006 per RXNORM
• UNII X05U0N2RCO per RXNORM

Indications